AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
NCT ID: NCT01483963
Last Updated: 2017-10-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2011-11-30
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 50 adult women and men are to be enrolled in this study. Following screening and determination of study eligibility, Assignment to Cohorts 1-4 is sequential. Subjects assigned to Cohorts 1 through 4 may receive up to 3 injections of AA4500 according to cohort assignment. Each injection will be separated by a minimum of 21 days. Subjects assigned to Cohort 5 will receive home shoulder exercises only, while subjects assigned to Cohorts 1-4 will receive AA4500 and home shoulder exercises. Subjects in Cohort 5 will be offered physical therapy sessions for a period of 2 months following completion of the study.
Dosing will range from 0.29 mg to 0.58 mg with varying volumes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AA4500 0.29 mg/1 mL
Up to three injections
AA4500 0.29 mg/1 mL
treatment of adhesive capsulitis
Shoulder exercises
Home shoulder exercises, minimum of 3 times per day
AA4500 0.58 mg/2 mL
Up to three injections
AA4500 0.58 mg/2 mL
treatment of adhesive capsulitis
Shoulder exercises
Home shoulder exercises, minimum of 3 times per day
AA4500 0.58 mg/1 mL
Up to three injections
AA4500 0.58 mg/1 mL
treatment of adhesive capsulitis
Shoulder exercises
Home shoulder exercises, minimum of 3 times per day
AA4500 0.58 mg/0.5 mL
Up to three injections
AA4500 0.58 mg/0.5 mL
treatment of adhesive capsulitis
Shoulder exercises
Home shoulder exercises, minimum of 3 times per day
Shoulder exercises
Home shoulder exercises for 64 days
Shoulder exercises
Home shoulder exercises, minimum of 3 times per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AA4500 0.29 mg/1 mL
treatment of adhesive capsulitis
AA4500 0.58 mg/2 mL
treatment of adhesive capsulitis
AA4500 0.58 mg/1 mL
treatment of adhesive capsulitis
AA4500 0.58 mg/0.5 mL
treatment of adhesive capsulitis
Shoulder exercises
Home shoulder exercises, minimum of 3 times per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. If a female of childbearing potential, have a negative urine pregnancy test and be using an effective contraception method (ie, abstinence, intrauterine device (IUD), hormonal (estrogen/progestin) contraceptives, or barrier control) for at least one menstrual cycle prior to study enrollment and for one menstrual cycle following end of study, or be surgically sterile
3. Have unilateral idiopathic adhesive capsulitis of one shoulder for at least 3 months but not more than 12 months before the screening visit and be in Stage 2 (frozen or adhesive stage), as determined by the investigator
4. Have normal range of motion in the contralateral shoulder, as determined by the investigator
5. Have restricted active range of motion (AROM) in the affected shoulder defined as: a deficit of at least 60 degrees in total AROM in the affected shoulder as compared with the total AROM in the contralateral shoulder and a deficit of at least 30 degrees in AROM in at least one of the following planes as compared with the contralateral shoulder:
* Forward flexion
* Abduction
* External rotation with the elbow up to 90 degrees abduction
* Internal rotation with the elbow up to 90 degrees abduction
6. Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution.
7. Be able to complete and understand the various rating instruments in English.
Exclusion Criteria
2. Is a male who intends to father a child during the study
3. Has received treatment for adhesive capsulitis or is planning to receive treatment for adhesive capsulitis at any time during the study including but not limited to:
* physical therapy or acupuncture within 2 weeks before the first injection of AA4500
* intra-articular or intrabursal injection(s) of lidocaine; suprascapular nerve blocks; corticosteroids; electroanalgesic and/or thermoanalgesic modalities within 1 month before the screening visit
* intra-articular or intrabursal injection(s) of sodium hyaluronate within 3 months before the screening visit
* glenohumeral distension arthrography and/or surgical intervention (including shoulder manipulation under anesthesia) at any time
4. Has any of the following conditions, as determined by the investigator:
* Adhesive capsulitis as a result of traumatic injury
* Pain in the affected shoulder at rest that is greater than or equal to 4 on the 11-point pain scale
* Active subacromial impingement in the affected shoulder
* Calcified tendonitis in the affected shoulder
* Glenohumeral joint arthritis in the affected shoulder
* Arthrosis of the affected shoulder
* Chondrolysis of the affected shoulder
* Subscapularis tendon rupture of the affected shoulder
* Other rotator cuff injuries of the affected shoulder
* Uncontrolled hypertension
* Uncontrolled diabetes
* Uncontrolled thyroid disease
* History of thrombosis or post-thrombosis syndrome
* Physical impairment that would preclude performing the protocol defined exercises
* Active infection in area to be treated
* Clinically significant neurological disease
* Coagulation disorder, using anticoagulant (except for less than or equal to 150 mg aspirin) within 7 days prior to each injection day
* Known active hepatitis B or C (history of hepatitis A permitted)
* Other significant medical condition (eg, morbid obesity, cervical disc disease), which in the investigator's opinion would make the subject unsuitable for enrollment in the study
5. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits.
6. Has received oral or intravenous steroids for any reason within 3 weeks before the screening visit
7. Has received an investigational drug or treatment within 30 days before the first dose of study drug.
8. Has a known systemic allergy to collagenase or any other excipient of AA4500 or any other procedural medication.
9. Has, at any time, received collagenase for the treatment of adhesive capsulitis.
10. Is unable to undergo an x-ray or MRI (contraindication) evaluation of the affected shoulder.
11. Is planning to be treated with commercial Xiaflex at any time during the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Endo Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Neil H Shusterman, MD FACP
Role: STUDY_DIRECTOR
Endo Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Orthopaedic Center - Research
Birmingham, Alabama, United States
HOPE Research Institute
Phoenix, Arizona, United States
Tucson Orthopaedic Institute
Tucson, Arizona, United States
OrthoArkansas
Little Rock, Arkansas, United States
CORE Orthopaedic Medical Center
Encinitas, California, United States
Triwest Research Associates
La Mesa, California, United States
Advent Clinical Research
Pinellas Park, Florida, United States
Rockford Orthopedic Associates
Rockford, Illinois, United States
The Indiana Hand to Shoulder Center
Indianapolis, Indiana, United States
Stony Brook University Medical Center
Stony Brook, New York, United States
David R. Mandel, MD, Inc.
Cleveland, Ohio, United States
Health Research Institute
Oklahoma City, Oklahoma, United States
Blair Orthopedic Associates, Inc.
Altoona, Pennsylvania, United States
Alpha Clinical Research, LLC
Clarksville, Tennessee, United States
Basin Orthopedic Surgical Specialists
Odessa, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUX-CC-870
Identifier Type: -
Identifier Source: org_study_id